SANTA CRUZ BIOTECHNOLOGY, INC.

CD21 (21-260): sc-4528 WB

The Power to Question

BACKGROUND

CD21 is a type I integral membrane glycoprotein that serves as a receptor for the C3d complement fragment and for the Epstein-Barr virus. It plays a role in B cell activation and proliferation and undergoes phosphorylation after B cell activation with phorbol esters. CD21 is expressed on mature B cells, follicular dendritic cells, pharyngeal and cervical epithelial cells, and a subset of thymocytes. The adaptive immune response is tightly regulated to limit responding cells in an antigen-specific manner. On B cells, co-receptors CD21/CD19 modulate the strength of B cell Ag receptor (BCR) signals, thereby influencing cell fate. Complement receptor (CR) type 2 (CR2/CD21) is normally expressed during the immature and mature stages of B cell development. In association with CD19, CR21 plays an important role in enhancing mature B cell responses to foreign antigen.

REFERENCES

1. Tanner, J., Weis, J., Fearon, D., Whang, Y. and Kieff, E. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell 50: 203-213.
2. Ahearn, J.M. and Fearon, D.T. 1989. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 46: 183-219.
3. Tedder, Z.F., Zhou, L.J. and Engel, P. 1994. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 15: 437-442.
4. Molina, H., Perkins, S.J., Guthridge, J., Gorka, J., Kinoshita, T. and Holers, V.M. 1995. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules. J. Immunol. 154: 5426-5435.
5. Roberts, M.L., Luxembourg, A.T. and Cooper, N.R. 1996. Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. J. Gen. Virol. 77: 3077-3085.
6. Sugano, N., Chen, W., Roberts, M.L. and Cooper, N.R. 1997. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NFκB induction. J. Exp. Med. 186: 731-737.
7. Shubinsky, G., Schlesinger, M., Polliack, A. and Rabinowitz, R. 1997. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc ε RII) proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530.
8. Twohig, J., Kulik, L., Haluszczak, C., Reuter, J., Rossbach, A., Bull, M., Holers, V.M. and Marchbank, K.J. 2007. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol. Immunol. 44: 3434-3444.
9. Yakushijin, Y., Shikata, H., Kito, K., Ohshima, K., Kojima, K., Hato, T., Hasegawa, H. and Yasukawa, M. 2007. Follicular dendritic cell tumor as an unknown primary tumor. Int. J. Clin. Oncol. 12: 56-58.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: CR2 (human) mapping to 1q32; Cr2 (mouse) mapping to 1 H6.

SOURCE

CD21 (21-260) is expressed in *E. coli* as a 55 kDa tagged fusion protein corresponding to amino acids 21-260 of CD21 of human origin.

PRODUCT

CD21 (21-260) is purified from bacterial lysates (>98%) by glutathione agarose affinity chromatography; supplied as 10 µg in 0.1 ml SDS-PAGE loading buffer.

APPLICATIONS

CD21 (21-260) is suitable as a Western blotting control for sc-9151 and sc-13135.

STORAGE

Store at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.